Osteoporosis management: Translating research into optimal fracture protection II

Current Medical Research and Opinion

Volumn 24, Issue 6, 2008, Pages 1789-1796

  Singer, Andrea J ^a   Boonen, Steven ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bone mineral density; Fracture risk; Nonpharmacologic management; Osteoporosis; Pharmacologic management

Indexed keywords

ALENDRONIC ACID; ALUMINUM; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CORTICOTROPIN; CYTOTOXIC AGENT; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; LITHIUM; PLACEBO; PROGESTERONE; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ARTHRALGIA; BONE MINERAL; BONE NECROSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; MYALGIA; NAUSEA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SECONDARY OSTEOPOROSIS; TREATMENT PLANNING; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; VOMITING;

COST-BENEFIT ANALYSIS; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SELECTION; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 46449112032     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802115887     Document Type: Review

References (63)

1. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation, 2003
2. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following fracture. Arch Intern Med 2003;163:2052-57
3. Majumdar SR, Rowe BH, Folk D, et al. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 2004;141:366-73
4. Boonen S, Singer A. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture (part 1 of 2). Curr Med Res Opin 2008;24:1783-90
5. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603
6. Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006;38:694-700
7. World Health Organization. Prevention and management of osteoporosis. WHO Tech Rep Ser 2003;921:1-164
8. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39
9. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82
10. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3
11. Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003;14:879-83
12. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64
13. Saag KG, Morgan SL, Coa X. Bone health and disease. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Conditions. A Textbook of Rheumatology, 15th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:2487
14. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation, 2008
15. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004. Available at: www.hhs.gov/surgeongeneral/library/bonehealth/ [Last accessed 30 April 2007]
16. Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004;164:1113-20
17. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001;12:519-28
18. The World Health Organization Fracture risk assessment tool. Available at www.shef.ac.uk/FRAX [Last accessed 26 February 2008]
19. Kanis JA, Johnell O, Oden A, et al. FRAX™ and assessment of fracture probability in men and women from the UK. Osteoporos Int 2008. DOI 10.1007/s00198-007-0543-5
20. Dawson-Hughes B, Tosteson ANA, Melton III LJ, et al. Implications of absolute fracture risk assessment for osteoporo-sis practice guidelines in the USA. Osteoporos Int 2008. DOI 10.1007/s00198-008-0559-5
21. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-67
22. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006;119(4 Suppl 1):S25-31
23. Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005;20:2097-104
24. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23
25. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
26. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
27. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
28. Chesnut 3rd CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
29. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
30. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
31. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24
32. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999;9:461-8
33. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone 2005;37:651-4
34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998;280:2077-82
35. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
36. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
37. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. HORIZON Recurrent Fracture Trial. N Engl J Med 2007;357:1799-809
38. Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 2004;10:142-51
39. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34
40. Motheral BR, Fairman KA. The use of claim databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19:346-66
41. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11:533-6
42. Dunford J, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42
43. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27
44. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
45. Fosamax® (alendronate sodium) prescribing information. Whitehouse Station, NJ: Merck & Co., Inc., May 2007. Available at: www.merck.com/ product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf [Last accessed 8 November 2007]
46. Actonel® (risedronate sodium) prescribing information. Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc., May 2007. Available at: www.actonel.com/global/prescribing_information_aug.pdf [Last accessed 8 November 2007]
47. Boniva® (ibandronate sodium) prescribing information. Nutley, NJ: Roche Laboratories Inc., August 2006. Available at: www.rocheusa.com/products/ Boniva/PI.pdf [Last accessed April 30 2007]
48. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61
49. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
50. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
51. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonates dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
52. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
53. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
54. Emkey R, Koltun W, Beusterinen K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
55. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;28:1023-31
56. Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2007 Dec 18 [Epub ahead of print]
57. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of Risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42
58. Reclastl® (zoledronic acid) prescribing information. Stein, Switzerland: Novartis Pharma Stein AG. Available at: www.pharma.us.novartis.com/ product/pi/pdf/reclast.pdf [Last accessed 25 February 2008]
59. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 2006;17:29-40
60. Ström O, Borgström F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18:1047-61
61. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004;15:862-71
62. Brixner D. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. Am J Manag Care 2006;12:S191-8
63. Jansen JP, Gaugris S, Bergman G, et al. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and the Netherlands. Curr Med Res Opin 2008 Jan 24 [Epub ahead of print]